---
document_datetime: 2025-12-01 15:28:59
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/benepali-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: benepali-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3122072
conversion_datetime: 2025-12-15 06:01:57.772975
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Benepali

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type IB /  | This was an application for a group of | 01/12/2025                          |                                             | SmPC, Annex                      | To update Annex IID and the Patient Card of the |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000304814   | variations. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other obligations and conditions (e.g. agreed wording + QRD template) - Accepted C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Annex IID and the Patient Card of the SmPC to remove the adverse effect 'congestive heart failure', following assessment of the same change for the reference product Enbrel. In addition, the MAH took the opportunity to update the EMA website address throughout the PI to align with the QRD template. C.I.11.z (Type IB) - To update the RMP to remove the important risks of 'Aplastic Anaemia and Pancytopenia', 'Congestive Heart Failure in Adult Subjects' and 'Acute Ischaemic Cardiovascular Events in Adults Subjects' in alignment with the RMP of the reference   | II and PL   | SmPC to remove the adverse effect 'congestive heart failure', following assessment of the same change for the reference product Enbrel. In addition, the MAH took the opportunity to update the EMA website address throughout the PI to align with the QRD template. To update the RMP to remove the important risks of 'Aplastic Anaemia and Pancytopenia', 'Congestive Heart Failure in Adult Subjects' and 'Acute Ischaemic Cardiovascular Events in Adults Subjects' in alignment with the RMP of the reference product.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000263971 | This was an application for a group of variations. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted A grouped application consisting of: C.I.13: Submission of the final report from study (ARTIS) listed as a category 3 study in the RMP. This is a national prospective, observational, uncontrolled cohort study whose objectives are to evaluate the risk of selected AEs in RA, juvenile idiopathic arthritis, and other rheumatic disease patients treated with etanercept. The RMP version 10.0 has also been submitted. C.I.13: Submission of the final report from study (BSRBR-RA) listed as a category 3 study in the RMP. This is an established nationwide register for patients with | 10/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | biologic agents.                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |    |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|
| Variation type IB / EMA/VR/0000263549 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted | 12/05/2025 | N/A |    |
| Variation type IB / EMA/VR/0000253630 | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted                                                                                                                                                                                              | 20/03/2025 | N/A |    |
| Article 61(3) / EMA/N/0000255572      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives.                                                                                                                                                                                                                                                                                           | 05/03/2025 |     | PL |